Emerging drugs for asthma

Walsh, Garry Michael

doi:10.1517/14728210802591378

Cited by 23 publications

(6 citation statements)

References 64 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibition of airway inflammation is believed to be one of the most important therapeutic goals in asthma (1, 3) as inflammation is present in the airways of most patients with asthma, and corticosteroids are the most effective agents in these patients (19). As corticosteroids possess potent immunosuppressive and toxic effects, specific inhibitors of airway inflammation with the potential for less toxicity have been studied (20), although those targeting only one mediator or one cell type have had limited or no success.…”

Section: Discussionmentioning

confidence: 99%

Dose-response effects of TPI ASM8 in asthmatics after allergen

Gauvreau

Pageau

Séguin

et al. 2011

Allergy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Dose-response effects of TPI ASM8 in asthmatics after allergen

Gauvreau

Pageau

Séguin

et al. 2011

Allergy

View full text Add to dashboard Cite

show abstract

“…Even today, the mortality rate is high and the efficiency of pharmacological therapy is limited in allergic asthma ( 13 , 14 ). Thus, it is necessary to investigate promising anti-inflammatory therapies that have few adverse effects and can be combined with other therapies.…”

Section: Introductionmentioning

confidence: 99%

Transfer factors peptides (Imuno TF®) modulate the lung inflammation and airway remodeling in allergic asthma

et al. 2023

View full text Add to dashboard Cite

BackgroundAllergic asthma is a chronic lung disease in which the lung inflammation and airway remodeling are orchestrated by both the inflammatory and the immune cells that creates a lung millieu that favors the perpetuation of clinical symptoms. The cell signaling in asthma involves the mast cells activation during initial contact with the allergen and, principally, the participation of eosinophils as well as Th2 cells which determine increased levels of IgE, exaggerated secretion of mucus and collagen, and bronchial hyperreactivity. Moreover, allergic asthma presents lower level of cytokines associated to the both Th1 and Treg cells response, and it implies in deficiency of anti-inflammatory response to counterregulate the exaggerated inflammation against allergen. Therefore, the equilibrium between cytokines as well as transcription factors associated to Th2, Th1, and Treg cells is compromised in allergic asthma. Imuno TF® is a food supplement with ability to interfere in immune system pathways. It has been previously demonstrated that Imuno TF® upregulated Th1 cell response whilst downregulated Th2 cell response in human lymphocytes.ObjectiveFor this reason, we hypothesized that the Imuno TF effect could be restore the balance between Th1/Th2 CD4 T cells response in murine allergic asthma.MethodsInitially, animals were sensitized with OVA via i.p. and challenged with OVA i.n. on days 14, 15 and 16. Treatment with Imuno TF once a day was performed via orogastric from day 17 to day 20. Mice were euthanized on day 21.ResultsThe Imuno TF reduced eosinophilia, mucus production, and airway remodeling (collagen deposition) in asthma mice. Imuno TF influenced cellular signaling associated to allergic asthma once downregulated STAT6 expression as well as decreased IL-4, IL-5, and IL-13 in lung and serum. In addition, Imuno TF restored T-bet and Foxp3 expression as well as increased IL-12, IFN-ɣ, and IL-10.ConclusionUltimately, Imuno TF mitigated the allergic asthma due to the restoration of balance between the responses of Th1/Th2 as well as Treg cells, and their respective transcription factors the T-bet/STAT6 and Foxp3.

show abstract

“…Bronchial asthma is among the most common chronic respiratory diseases (1)(2)(3). This disease generates a pulmonary inflammatory response that is mitigated by non-curative treatments that have serious side effects (4,5). A lot of research has been invested in the search for new drugs to treat this condition.…”

Section: Introductionmentioning

confidence: 99%

Photobiomodulation Therapy Restores IL-10 Secretion in a Murine Model of Chronic Asthma: Relevance to the Population of CD4+CD25+Foxp3+ Cells in Lung

Brito¹,

Herculano²,

Estefano-Alves³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

It is largely known that photobiomodulation (PBM) has beneficial effects on allergic pulmonary inflammation. Our previous study showed an anti-inflammatory effect of the PBM in an acute experimental model of asthma, and we see that this mechanism is partly dependent on IL-10. However, it remains unclear whether the activation of regulatory T cells is mediated by PBM in a chronic experimental model of asthma. In this sense, the objective of this study was to verify the anti-inflammatory role of the PBM in the pulmonary inflammatory response in a chronic experimental asthma model. The protocol used for asthma induction was the administration of OVA subcutaneously (days 0 and 14) and intranasally (3 times/week, for 5 weeks). On day 50, the animals were sacrificed for the evaluation of the different parameters. The PBM used was the diode, with a wavelength of 660 nm, a power of 100 mW, and 5 J for 50 s/point, in three different application points. Our results showed that PBM decreases macrophages, neutrophils, and lymphocytes in the bronchoalveolar lavage fluid (BALF). Moreover, PBM decreased the release of cytokines by the lung, mucus, and collagen in the airways and pulmonary mechanics. When we analyzed the percentage of Treg cells in the group irradiated with laser, we verified an increase in these cells, as well as the release of IL-10 in the BALF. Therefore, we conclude that the use of PBM therapy in chronic airway inflammation attenuated the inflammatory process, as well as the pulmonary functional and structural parameters, probably due to an increase in Treg cells.

show abstract

Emerging drugs for asthma

Cited by 23 publications

References 64 publications

Dose-response effects of TPI ASM8 in asthmatics after allergen

Dose-response effects of TPI ASM8 in asthmatics after allergen

Transfer factors peptides (Imuno TF®) modulate the lung inflammation and airway remodeling in allergic asthma

Photobiomodulation Therapy Restores IL-10 Secretion in a Murine Model of Chronic Asthma: Relevance to the Population of CD4+CD25+Foxp3+ Cells in Lung

Contact Info

Product

Resources

About